These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 37907837

  • 21. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
    Jo JH, Chung HW, Kim SY, Lee MH, So Y.
    Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
    [Abstract] [Full Text] [Related]

  • 22. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
    Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W.
    Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method.
    Rekowski J, Hüttmann A, Schmitz C, Müller SP, Kurch L, Kotzerke J, Franzius C, Weckesser M, Bengel FM, Freesmeyer M, Hertel A, Krohn T, Holzinger J, Brink I, Haberkorn U, Nyuyki F, van Assema DME, Geworski L, Hasenclever D, Jöckel KH, Dührsen U.
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [Abstract] [Full Text] [Related]

  • 25. [The Prognosis Assessment Value of Interim 18F-FDG PET/CT Imaging in the Chemotherapy of Diffuse Large B-cell Lymphoma].
    Peng XJ, Kou Y, Yu SS, Yao YT, Jiang XM, You JH, Zhang ZH, Chen SR, Jiang X, Cheng ZZ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1440-1445. PubMed ID: 36208247
    [Abstract] [Full Text] [Related]

  • 26. Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma.
    Duarte S, Roque A, Saraiva T, Afonso C, Marques BA, Lima CB, Neves D, Lai AC, Costa G, Cipriano A, Geraldes C, Ruzickova L, Carda JP, Gomes M.
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [Abstract] [Full Text] [Related]

  • 27. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L.
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [Abstract] [Full Text] [Related]

  • 32. [Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Patients with Diffuse Large B-Cell Lymphoma].
    Su JM, Zheng QZ, Huang WR, Deng J, Wu J, Lu HQ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†.
    Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I.
    Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with 18F-FDG PET/CT, in patients with diffuse large cell B-cell lymphoma.
    Guzmán Ortiz S, Mucientes Rasilla J, Vargas Núñez JA, Royuela A, Navarro Matilla B, Mitjavila Casanovas M.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Mar; 39(6):340-346. PubMed ID: 32646783
    [Abstract] [Full Text] [Related]

  • 37. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
    Kwon SH, Kang DR, Kim J, Yoon JK, Lee SJ, Jeong SH, Lee HW, An YS.
    Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
    Wang F, Cui S, Lu L, Shao X, Yan F, Liu Y, He B, Wang J, Cao Y, Yue Y, Wang Y, Gu W.
    BMC Cancer; 2023 Nov 29; 23(1):1165. PubMed ID: 38030989
    [Abstract] [Full Text] [Related]

  • 40. 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Metabolic Parameters Before and After Neoadjuvant Chemotherapy Can Predict the Postoperative Prognosis of Locally Advanced Gastric Cancer.
    Mi L, Zhao Y, Zhao X, Yin F, Yin X, Li N, Shi J, Han X, Duan X, Zhao M, Han G, Wang J.
    Cancer Biother Radiopharm; 2021 Oct 29; 36(8):662-671. PubMed ID: 32783634
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.